RU2015132436A - Способы обнаружения активности протеазы в биологических системах и композиции для их осуществления - Google Patents
Способы обнаружения активности протеазы в биологических системах и композиции для их осуществления Download PDFInfo
- Publication number
- RU2015132436A RU2015132436A RU2015132436A RU2015132436A RU2015132436A RU 2015132436 A RU2015132436 A RU 2015132436A RU 2015132436 A RU2015132436 A RU 2015132436A RU 2015132436 A RU2015132436 A RU 2015132436A RU 2015132436 A RU2015132436 A RU 2015132436A
- Authority
- RU
- Russia
- Prior art keywords
- activated antibody
- target
- activated
- seq
- subject
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 33
- 108091005804 Peptidases Proteins 0.000 title claims 7
- 239000004365 Protease Substances 0.000 title claims 7
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 title claims 6
- 239000000203 mixture Substances 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 13
- 102000004196 processed proteins & peptides Human genes 0.000 claims 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 239000012472 biological sample Substances 0.000 claims 6
- 229920001184 polypeptide Polymers 0.000 claims 6
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 210000004899 c-terminal region Anatomy 0.000 claims 3
- 238000003776 cleavage reaction Methods 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 230000007017 scission Effects 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 239000003153 chemical reaction reagent Substances 0.000 claims 2
- 238000010494 dissociation reaction Methods 0.000 claims 2
- 230000005593 dissociations Effects 0.000 claims 2
- 239000000523 sample Substances 0.000 claims 2
- 239000000758 substrate Substances 0.000 claims 2
- JARGNLJYKBUKSJ-KGZKBUQUSA-N (2r)-2-amino-5-[[(2r)-1-(carboxymethylamino)-3-hydroxy-1-oxopropan-2-yl]amino]-5-oxopentanoic acid;hydrobromide Chemical compound Br.OC(=O)[C@H](N)CCC(=O)N[C@H](CO)C(=O)NCC(O)=O JARGNLJYKBUKSJ-KGZKBUQUSA-N 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 102000035195 Peptidases Human genes 0.000 claims 1
- 206010039509 Scab Diseases 0.000 claims 1
- 239000002872 contrast media Substances 0.000 claims 1
- 239000000975 dye Substances 0.000 claims 1
- 239000007850 fluorescent dye Substances 0.000 claims 1
- 108010044804 gamma-glutamyl-seryl-glycine Proteins 0.000 claims 1
- 108700026078 glutathione trisulfide Proteins 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 238000011065 in-situ storage Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 150000002500 ions Chemical class 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 230000000873 masking effect Effects 0.000 claims 1
- 229910052751 metal Inorganic materials 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- 150000002739 metals Chemical class 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- 125000006850 spacer group Chemical group 0.000 claims 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0058—Antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (17)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361749212P | 2013-01-04 | 2013-01-04 | |
| US201361749220P | 2013-01-04 | 2013-01-04 | |
| US61/749,220 | 2013-01-04 | ||
| US61/749,212 | 2013-01-04 | ||
| US201361749529P | 2013-01-07 | 2013-01-07 | |
| US201361749486P | 2013-01-07 | 2013-01-07 | |
| US61/749,486 | 2013-01-07 | ||
| US61/749,529 | 2013-01-07 | ||
| US201361755810P | 2013-01-23 | 2013-01-23 | |
| US61/755,810 | 2013-01-23 | ||
| US201361763237P | 2013-02-11 | 2013-02-11 | |
| US61/763,237 | 2013-02-11 | ||
| US201361830940P | 2013-06-04 | 2013-06-04 | |
| US61/830,940 | 2013-06-04 | ||
| US201361897659P | 2013-10-30 | 2013-10-30 | |
| US61/897,659 | 2013-10-30 | ||
| PCT/US2014/010216 WO2014107599A2 (en) | 2013-01-04 | 2014-01-03 | Compositions and methods for detecting protease activity in biological systems |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2015132436A true RU2015132436A (ru) | 2017-02-09 |
Family
ID=51062553
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015132436A RU2015132436A (ru) | 2013-01-04 | 2014-01-03 | Способы обнаружения активности протеазы в биологических системах и композиции для их осуществления |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US10261083B2 (enExample) |
| EP (1) | EP2941643A4 (enExample) |
| JP (3) | JP6605957B2 (enExample) |
| CN (2) | CN112162094A (enExample) |
| AU (2) | AU2014204015A1 (enExample) |
| CA (1) | CA2896282C (enExample) |
| HK (1) | HK1210831A1 (enExample) |
| RU (1) | RU2015132436A (enExample) |
| WO (1) | WO2014107599A2 (enExample) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2754072C (en) | 2009-03-02 | 2019-01-15 | Massachusetts Institute Of Technology | Methods and products for in vivo enzyme profiling |
| CA3214092A1 (en) | 2011-03-15 | 2012-09-20 | Massachusetts Institute Of Technology | Multiplexed detection with isotope-coded reporters |
| GB201203442D0 (en) | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
| CA2876904C (en) | 2012-06-22 | 2019-12-03 | Cytomx Therapeutics, Inc. | Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof |
| CN112162094A (zh) | 2013-01-04 | 2021-01-01 | 西托姆克斯治疗公司 | 用于检测生物系统中的蛋白酶活性的组合物和方法 |
| EP3003387A1 (en) * | 2013-06-04 | 2016-04-13 | Cytomx Therapeutics Inc. | Compositions and methods for conjugating activatable antibodies |
| JP6847660B2 (ja) | 2013-06-07 | 2021-03-24 | マサチューセッツ インスティテュート オブ テクノロジー | リガンドをコードする合成バイオマーカーのアフィニティベースの検出 |
| CA2918795A1 (en) * | 2013-07-25 | 2015-01-29 | Cytomx Therapeutics, Inc. | Multispecific antibodies, multispecific activatable antibodies and methods of using the same |
| IL291329B1 (en) | 2013-09-25 | 2025-09-01 | Cytomx Therapeutics Inc | Polypeptides that can be determined in matrix metalloproteinases and uses thereof |
| US9540440B2 (en) | 2013-10-30 | 2017-01-10 | Cytomx Therapeutics, Inc. | Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof |
| US9737623B2 (en) | 2013-12-11 | 2017-08-22 | Cytomx Therapeutics, Inc. | Antibodies that bind activatable antibodies and methods of use thereof |
| CN106459153B (zh) | 2014-01-31 | 2021-12-21 | 西托姆克斯治疗公司 | 蛋白裂解酶和u型纤溶酶原激活物的底物和其它可裂解部分及其使用方法 |
| WO2016014974A2 (en) | 2014-07-25 | 2016-01-28 | Cytomx Therapeutics, Inc. | Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same |
| EP3183366B1 (en) * | 2014-08-18 | 2022-10-19 | Adrastia Biotech Corporation | Systems and methods of detecting solid tumor cancer |
| EP3244907B1 (en) | 2015-01-13 | 2020-02-19 | City of Hope | Ctla4-binding protein peptide-linker masks |
| MA41374A (fr) * | 2015-01-20 | 2017-11-28 | Cytomx Therapeutics Inc | Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci |
| MX2017011644A (es) | 2015-03-13 | 2017-12-04 | Cytomx Therapeutics Inc | Anticuerpos anti-pdl1, anticuerpos anti-pdl1 activables y metodos de uso de los mismos. |
| AU2016257929B2 (en) | 2015-05-04 | 2022-10-20 | Cytomx Therapeutics, Inc | Anti-CD166 antibodies, activatable anti-CD166 antibodies, and methods of use thereof |
| CN107849144B (zh) | 2015-05-29 | 2021-09-17 | 艾吉纳斯公司 | 抗-ctla-4抗体及其使用方法 |
| WO2016204966A1 (en) | 2015-06-16 | 2016-12-22 | Genentech, Inc. | Anti-cd3 antibodies and methods of use |
| US10822419B2 (en) | 2015-06-26 | 2020-11-03 | University Of Southern California | Masking chimeric antigen receptor T cells for tumor-specific activation |
| CN106519037B (zh) * | 2015-09-11 | 2019-07-23 | 科济生物医药（上海）有限公司 | 可活化的嵌合受体 |
| AU2016358296B2 (en) | 2015-11-19 | 2020-05-21 | Revitope Limited | Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells |
| EP4089166A1 (en) | 2016-01-27 | 2022-11-16 | Oncorus, Inc. | Oncolytic viral vectors and uses thereof |
| US10358496B2 (en) | 2016-03-01 | 2019-07-23 | Ralf Kleef | Low dose immune checkpoint blockade in metastatic cancer |
| US11448643B2 (en) | 2016-04-08 | 2022-09-20 | Massachusetts Institute Of Technology | Methods to specifically profile protease activity at lymph nodes |
| WO2017193070A1 (en) | 2016-05-05 | 2017-11-09 | Massachusetts Institute Of Technology | Methods and uses for remotely triggered protease activity measurements |
| FI3551660T3 (fi) | 2016-12-07 | 2023-12-11 | Agenus Inc | Anti-ctla-4-vasta-aineita ja niiden käyttömenetelmiä |
| EP3551225A1 (en) | 2016-12-07 | 2019-10-16 | Agenus Inc. | Antibodies and methods of use thereof |
| CN110036034A (zh) | 2016-12-09 | 2019-07-19 | 西雅图遗传学公司 | 卷曲螺旋掩蔽的二价抗体 |
| AU2018248327B2 (en) | 2017-04-07 | 2024-10-10 | Massachusetts Institute Of Technology | Methods to spatially profile protease activity in tissue and sections |
| EP3630838A1 (en) | 2017-06-01 | 2020-04-08 | CytomX Therapeutics, Inc. | Activatable anti-pdl1 antibodies, and methods of use thereof |
| US11220544B2 (en) | 2017-07-14 | 2022-01-11 | Cytomx Therapeutics, Inc. | Anti-CD166 antibodies and uses thereof |
| KR20200042904A (ko) | 2017-07-26 | 2020-04-24 | 온코루스, 인크. | 종양용해성 바이러스 벡터 및 그의 용도 |
| IL321773A (en) | 2017-10-14 | 2025-08-01 | Cytomx Therapeutics Inc | Activatable antibodies and methods for preparing them |
| AR113862A1 (es) | 2017-12-01 | 2020-06-17 | Seattle Genetics Inc | Anticuerpos anti-cd47 y sus usos para tratar cáncer |
| MX2020008289A (es) | 2018-02-08 | 2020-09-25 | Genentech Inc | Moleculas biespecificas de union al antigeno y metodos de uso. |
| US11054428B2 (en) | 2018-03-05 | 2021-07-06 | Massachusetts Institute Of Technology | Inhalable nanosensors with volatile reporters and uses thereof |
| EP3769309A1 (en) | 2018-03-20 | 2021-01-27 | Cytomx Therapeutics Inc. | Systems and methods for quantitative pharmacological modeling of activatable antibody species in mammalian subjects |
| MX2020012252A (es) | 2018-05-14 | 2021-04-28 | Werewolf Therapeutics Inc | Polipeptidos de interleucina 12 activables y metodos de uso de los mismos. |
| CN113840832A (zh) | 2018-05-14 | 2021-12-24 | 狼人治疗公司 | 可活化白介素-2多肽及其使用方法 |
| US20210322508A1 (en) * | 2018-08-13 | 2021-10-21 | Signablok, Inc. | Peptides and compositions for targeted treatment and imaging |
| WO2020068920A2 (en) | 2018-09-25 | 2020-04-02 | Massachusetts Institute Of Technology | Lung protease nanosensors and uses thereof |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| CA3120327A1 (en) | 2018-12-06 | 2020-06-11 | Cytomx Therapeutics, Inc. | Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof |
| BR112021012631A2 (pt) * | 2018-12-26 | 2021-12-14 | Xilio Dev Inc | Anticorpos anti-ctla4 e métodos de uso dos mesmos |
| EP3911753A1 (en) | 2019-01-17 | 2021-11-24 | Massachusetts Institute of Technology | Sensors for detecting and imaging of cancer metastasis |
| EP3969035A4 (en) | 2019-05-14 | 2023-06-21 | Werewolf Therapeutics, Inc. | SEPARATION UNITS AND METHODS AND THEIR USE |
| KR102503349B1 (ko) | 2019-05-14 | 2023-02-23 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
| WO2020236679A1 (en) * | 2019-05-17 | 2020-11-26 | Cytomx Therapeutics, Inc. | Methods and compositions for determining the biodistribution of activatable anti-cd166 antibody conjugates |
| US20220306727A1 (en) | 2019-06-05 | 2022-09-29 | Seagen Inc. | Methods of Purifying Masked Antibodies |
| US20220233709A1 (en) | 2019-06-05 | 2022-07-28 | Seagen Inc. | Masked Antibody Formulations |
| WO2021097376A1 (en) | 2019-11-14 | 2021-05-20 | Werewolf Therapeutics, Inc. | Activatable cytokine polypeptides and methods of use thereof |
| BR112022011357A2 (pt) | 2019-12-13 | 2022-08-23 | Genentech Inc | Anticorpos isolado, um ou mais ácidos nucleicos isolados, um ou mais vetores, uma ou mais células hospedeiras, composição, kit, uso do anticorpo, métodos para produzir o anticorpo e método para tratar ou retardar a progressão de um câncer ly6g6d positivo |
| KR20220166814A (ko) | 2020-04-09 | 2022-12-19 | 싸이톰스 테라퓨틱스, 인크. | 활성화 가능한 항체를 함유하는 조성물 |
| US12006366B2 (en) | 2020-06-11 | 2024-06-11 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| CN111830254B (zh) * | 2020-07-29 | 2022-07-26 | 武汉生之源生物科技股份有限公司 | 一种基质金属蛋白酶-3测定试剂盒及其制备方法 |
| CN114859042B (zh) * | 2021-02-03 | 2023-11-03 | 广东菲鹏生物有限公司 | 一种鉴别结合突变型抗原的抗体的方法及试剂 |
| EP4370211A1 (en) | 2021-07-14 | 2024-05-22 | Seagen Inc. | Antibody masking domains |
| EP4377453A4 (en) * | 2021-07-26 | 2025-09-03 | Georgia Tech Res Inst | COMPOSITIONS AND METHODS FOR IN VIVO PROTEASE PROFILING BY DISPLAYING IMMUNE CELLS |
| WO2023034825A1 (en) * | 2021-08-30 | 2023-03-09 | Cytomx Therapeutics, Inc. | Method for determining protease activity in a biological sample |
| US20240376200A1 (en) | 2021-09-24 | 2024-11-14 | Seagen Inc. | Improved Antibody Masking Domains |
| WO2023168239A2 (en) * | 2022-03-01 | 2023-09-07 | The Board Of Regents Of The University Of Texas System | Methods for identifying lilrb ligands and blocking antibodies |
| CA3247048A1 (en) | 2022-04-13 | 2023-10-19 | Genentech Inc | PHARMACEUTICAL COMPOSITIONS OF MOSUNETUZUMAB AND METHODS OF USE |
| WO2025240659A2 (en) | 2024-05-14 | 2025-11-20 | Cytomx Therapeutics, Inc. | Activatable constructs, compositions and methods |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1286700A2 (en) | 2000-06-01 | 2003-03-05 | Universite Catholique De Louvain | Tumor activated prodrug compounds |
| US7465790B2 (en) | 2000-10-09 | 2008-12-16 | Isis Innovation, Inc. | Therapeutic antibodies |
| AU9399501A (en) | 2000-10-09 | 2002-04-22 | Isis Innovation | Therapeutic antibodies |
| US20040109855A1 (en) | 2002-07-23 | 2004-06-10 | Herman Waldmann | Therapeutic antibodies with reduced side effect |
| WO2004021861A2 (en) | 2002-09-03 | 2004-03-18 | Vit Lauermann | Targeted release |
| AU2006284651C1 (en) | 2005-08-31 | 2013-09-12 | The Regents Of The University Of California | Cellular libraries of peptide sequences (CLiPS) and methods of using the same |
| CA2645347A1 (en) | 2006-03-10 | 2007-09-20 | Diatos | Anticancer drugs conjugated to antibody via an enzyme cleavable linker |
| EP2514767A1 (en) * | 2006-12-19 | 2012-10-24 | Ablynx N.V. | Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders |
| US8293685B2 (en) | 2007-07-26 | 2012-10-23 | The Regents Of The University Of California | Methods for enhancing bacterial cell display of proteins and peptides |
| EP3492488A1 (en) * | 2007-08-22 | 2019-06-05 | The Regents of The University of California | Activatable binding polypeptides and methods of identification and use thereof |
| EP2356131A4 (en) | 2008-12-08 | 2012-09-12 | Tegopharm Corp | MASKING LIGANDS FOR REVERSIBLE INHIBITION OF VERSATILE COMPOUNDS |
| US20110178279A1 (en) * | 2009-08-03 | 2011-07-21 | Williams John C | Development of masked therapeutic antibodies to limit off-target effects: application to anti-egfr antibodies |
| WO2010081173A2 (en) * | 2009-01-12 | 2010-07-15 | Cytomx Therapeutics, Llc | Modified antibody compositions, methods of making and using thereof |
| US9309325B2 (en) | 2009-05-07 | 2016-04-12 | The Regents Of The University Of California | Antibodies and methods of use thereof |
| AU2013251310B2 (en) * | 2012-04-27 | 2018-02-15 | Cytomx Therapeutics, Inc. | Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof |
| CA2876904C (en) * | 2012-06-22 | 2019-12-03 | Cytomx Therapeutics, Inc. | Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof |
| CN112162094A (zh) | 2013-01-04 | 2021-01-01 | 西托姆克斯治疗公司 | 用于检测生物系统中的蛋白酶活性的组合物和方法 |
-
2014
- 2014-01-03 CN CN202010717082.7A patent/CN112162094A/zh active Pending
- 2014-01-03 EP EP14735246.2A patent/EP2941643A4/en active Pending
- 2014-01-03 CA CA2896282A patent/CA2896282C/en active Active
- 2014-01-03 CN CN201480011969.7A patent/CN105008918A/zh active Pending
- 2014-01-03 US US14/147,324 patent/US10261083B2/en active Active
- 2014-01-03 WO PCT/US2014/010216 patent/WO2014107599A2/en not_active Ceased
- 2014-01-03 RU RU2015132436A patent/RU2015132436A/ru unknown
- 2014-01-03 AU AU2014204015A patent/AU2014204015A1/en not_active Abandoned
- 2014-01-03 JP JP2015551784A patent/JP6605957B2/ja active Active
- 2014-01-03 HK HK15111420.0A patent/HK1210831A1/xx unknown
-
2018
- 2018-10-18 AU AU2018250437A patent/AU2018250437B2/en active Active
-
2019
- 2019-02-15 US US16/277,497 patent/US11035859B2/en active Active
- 2019-10-17 JP JP2019190445A patent/JP7001652B2/ja active Active
-
2021
- 2021-04-30 US US17/246,167 patent/US11867695B2/en active Active
- 2021-12-23 JP JP2021209234A patent/JP7223832B2/ja active Active
-
2023
- 2023-11-09 US US18/506,072 patent/US20240337658A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014107599A3 (en) | 2014-09-04 |
| CA2896282A1 (en) | 2014-07-10 |
| JP2020098195A (ja) | 2020-06-25 |
| US11867695B2 (en) | 2024-01-09 |
| CN105008918A (zh) | 2015-10-28 |
| US20140255313A1 (en) | 2014-09-11 |
| JP2022036134A (ja) | 2022-03-04 |
| EP2941643A4 (en) | 2016-09-28 |
| CA2896282C (en) | 2021-07-20 |
| JP7223832B2 (ja) | 2023-02-16 |
| HK1210831A1 (en) | 2016-05-06 |
| US10261083B2 (en) | 2019-04-16 |
| EP2941643A2 (en) | 2015-11-11 |
| AU2018250437A1 (en) | 2018-11-15 |
| US20240337658A1 (en) | 2024-10-10 |
| JP2016505138A (ja) | 2016-02-18 |
| CN112162094A (zh) | 2021-01-01 |
| JP7001652B2 (ja) | 2022-02-21 |
| US20200025761A1 (en) | 2020-01-23 |
| US20210382053A1 (en) | 2021-12-09 |
| AU2014204015A1 (en) | 2015-07-09 |
| AU2018250437B2 (en) | 2020-09-03 |
| WO2014107599A2 (en) | 2014-07-10 |
| US11035859B2 (en) | 2021-06-15 |
| JP6605957B2 (ja) | 2019-11-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2015132436A (ru) | Способы обнаружения активности протеазы в биологических системах и композиции для их осуществления | |
| JP2016505138A5 (enExample) | ||
| CA3109607C (en) | Methods and reagents for diagnosis of sars-cov-2 infection | |
| US9772328B2 (en) | Bimolecular protease-based biosensor | |
| ES2440597T3 (es) | Ensayos de actividad de endopeptidasa re-dirigida basados en inmunología | |
| ES2665996T3 (es) | Anticuerpo agonista de klotho-beta para utilizar en el tratamiento de diabetes mellitus o resistencia a la insulina | |
| Raynaud et al. | Calpain 1–titin interactions concentrate calpain 1 in the Z‐band edges and in the N2‐line region within the skeletal myofibril | |
| Guillon-Munos et al. | Kallikrein-related peptidase 12 hydrolyzes matricellular proteins of the CCN family and modifies interactions of CCN1 and CCN5 with growth factors | |
| RU2014147684A (ru) | Активируемые антитела, которые связываются с рецептором эпидермального фактора роста, и способы их применения | |
| RU2011108943A (ru) | Профилактика, лечение и диагностика инфекции, вызванной бактериями p.gingivalis | |
| JP2015516813A5 (enExample) | ||
| DK2904403T3 (en) | PROCEDURE FOR DIAGNOSTICATION OR MONITORING OF Kidney Function or Diagnosis of Kidney Function | |
| WO2018001309A1 (zh) | 一种检测血清中异常脱羧凝血酶原的蛋白芯片、试剂盒及其制备方法 | |
| WO2016065415A1 (en) | Bimolecular autoinhibited biosensor | |
| CN101988926A (zh) | 一种高尔基蛋白gp73的夹心elisa定量检测方法及其检测试剂盒 | |
| JP4593117B2 (ja) | 炎症性疾患および敗血症を診断するための、カルバモイルリン酸シンテターゼ１（ｃｐｓ１）およびその断片の使用 | |
| CN107001437A (zh) | 卵巢透明细胞腺癌的检查方法及检查药 | |
| DK1572225T3 (en) | THROMBOSPOND INFRAGMENTS AND APPLICATIONS THEREOF IN CLINICAL CANCER ASSAYS AND CREATION OF ANTIBODIES AND OTHER BINDING AGENTS | |
| JP6624755B2 (ja) | プロテインタグ、タグ化タンパク質及びタンパク質精製方法 | |
| CN111051889B (zh) | 检测癌症的方法和检测试剂 | |
| JP7546255B2 (ja) | 癌を検出する方法および検出試薬 | |
| RU2005115973A (ru) | Растворимые субстраты на основе notch для гамма-секретазы, а также способы и композиции для их применения | |
| CN108291915B (zh) | Ed-b蛋白在诊断组织增生中的应用 | |
| Ogura et al. | Proneurotensin/neuromedin N secreted from small cell lung carcinoma cell lines as a potential tumor marker | |
| US20160370382A1 (en) | Method for immunoassay of autoantibody against ku86, kit for use in same, and method for determination of primary hepatocellular carcinoma using same |